Eckert & Ziegler Radiopharma submitted an amendment to its drug master file to the U.S. Food and Drug Administration (FDA) for its GalliaPharm PET radiotracer.
GalliaPharm is based on germanium-68 (Ge-68)/gallium-68 (Ga-68) and is mainly used in combination with tracer kits for diagnosis of neuroendocrine tumors and prostate cancer on PET scans.
The company's proprietary Ge-68/Ga-68 generator will additionally be available in sizes of up to 100 mCi with a shelf-life of 12 months or for a maximum of 700 elutions. Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in PET.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
